Product NDC: | 0615-7716 |
Proprietary Name: | Cilostazol |
Non Proprietary Name: | Cilostazol |
Active Ingredient(s): | 50 mg/1 & nbsp; Cilostazol |
Administration Route(s): | ORAL |
Dosage Form(s): | TABLET |
Coding System: | National Drug Codes(NDC) |
Product NDC: | 0615-7716 |
Labeler Name: | NCS HealthCare of KY, Inc dba Vangard Labs |
Product Type: | HUMAN PRESCRIPTION DRUG |
FDA Application Number: | ANDA077027 |
Marketing Category: | ANDA |
Start Marketing Date: | 20120626 |
Package NDC: | 0615-7716-39 |
Package Description: | 30 TABLET in 1 BLISTER PACK (0615-7716-39) |
NDC Code | 0615-7716-39 |
Proprietary Name | Cilostazol |
Package Description | 30 TABLET in 1 BLISTER PACK (0615-7716-39) |
Product NDC | 0615-7716 |
Product Type Name | HUMAN PRESCRIPTION DRUG |
Non Proprietary Name | Cilostazol |
Dosage Form Name | TABLET |
Route Name | ORAL |
Start Marketing Date | 20120626 |
Marketing Category Name | ANDA |
Labeler Name | NCS HealthCare of KY, Inc dba Vangard Labs |
Substance Name | CILOSTAZOL |
Strength Number | 50 |
Strength Unit | mg/1 |
Pharmaceutical Classes | Phosphodiesterase 3 Inhibitor [EPC],Phosphodiesterase 3 Inhibitors [MoA] |